Continuous Positive Airway Pressure or Humidified High Flow Nasal Cannula for Respiratory Distress Syndrome: A Randomized Control Trial Among Premature Neonates Publisher



Shirvani TE¹ ; Nayeri FS² ; Shariat M³ ; Nafs NN¹ ; Mirjalili MR⁴ ; Hosseini SN¹ ; Ghorbansabagh V⁵ Show Affiliations
Source: Iranian Journal of Neonatology Published:2020

Abstract

Background: Respiratory distress syndrome (RDS) is a common lung problem in neonates born before 28 weeks of pregnancy. The current study aimed to assess the clinical outcomes of Nasal Continuous Positive Airway Pressure (NCPAP), as compared to humidified high flow nasal cannula (HHFNC) in the treatment of premature neonates with RDS. Methods: This randomized control trial was conducted on 60 preterm neonates (gestation <34 weeks and birth weight <2,000 g) with mild to moderate RDS (respiratory severity score of 4 to 7) and oxygen requirement 60% or less. They were randomly assigned to either NCPAP or HHFNC groups. Treatment failure in the irst 72 h after birth was the primary outcome. Secondary outcomes included Pneumothorax, patent ductus arteriosus (PDA), chronic lung disease, surfactant injection, tracheal intubation, necrotizing enterocolitis (NEC), several days of delay in establishing full enteral feeds, extended length of hospital stay and oxygen therapy days, and death. Data were analyzed in SPSS software (version 16) using independent t-test, chi-square, and logistic regression statistical tests at 95% signi icant level. Results: There were no significant differences in primary and secondary outcomes, including pneumothorax, patent ductus arteriosus (PDA), chronic lung disease, surfactant injection, tracheal intubation, death, necrotizing enterocolitis (NEC), days of delay in establishing full enteral feeds, duration of hospitalization, and the number of the days for oxygen requirement between NCPAP and HHFNC groups. Conclusion: HHFNC and NCPAP techniques have the same efficacy in the treatment of RDS in neonates, and there was no difference between the two techniques in terms of treatment failure and clinical outcomes. Since HHFNC is less invasive with the same efficacy compared to CPAP, we recommend that it can be used as a primary modality in preterm neonates with RDS. © 2020 Mashhad University of Medical Sciences. All rights reserved.